MA26728A1 - COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE CYP2D6 ET UN MÉDICAMENT à MÉTABOLISME CATALYSÉ PAR CYP2D6 - Google Patents

COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE CYP2D6 ET UN MÉDICAMENT à MÉTABOLISME CATALYSÉ PAR CYP2D6

Info

Publication number
MA26728A1
MA26728A1 MA25947A MA25947A MA26728A1 MA 26728 A1 MA26728 A1 MA 26728A1 MA 25947 A MA25947 A MA 25947A MA 25947 A MA25947 A MA 25947A MA 26728 A1 MA26728 A1 MA 26728A1
Authority
MA
Morocco
Prior art keywords
cyp2d6
pharmaceutical composition
inhibitor
catalyzed metabolism
metabolism drug
Prior art date
Application number
MA25947A
Other languages
English (en)
Inventor
Scott Obach Ronald
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26728A1 publication Critical patent/MA26728A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN MÉDICAMENT POUR LEQUEL LE MÉCANISME PRINCIPAL DE CLAIRANCE CHEZ L'HOMME CONSISTE EN UNE BIOTRANSFORMATION AXYDATIVE à MÉDIATION PAR CYP2D6 ET UN INHIBITEUR DE CYP2D6 NE CONSISTANT PAS EN LE MeME COMPOSÉ.ELLE CONCERNE ÉGALEMENT UN PROCÉDÉ POUR SA PRÉPARATION. APPLICATION : UTILISATION DE CETTE COMPOSITIOB POUR L'AMÉLIORATION DU PROFIL PHARMACOCÉNITIQUE DUDIT MÉDICAMENT POUR LE TRAITEMENT DE DIVERSES MALADIES.
MA25947A 1999-04-07 2000-04-05 COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE CYP2D6 ET UN MÉDICAMENT à MÉTABOLISME CATALYSÉ PAR CYP2D6 MA26728A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12813699P 1999-04-07 1999-04-07

Publications (1)

Publication Number Publication Date
MA26728A1 true MA26728A1 (fr) 2004-12-20

Family

ID=22433828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25947A MA26728A1 (fr) 1999-04-07 2000-04-05 COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE CYP2D6 ET UN MÉDICAMENT à MÉTABOLISME CATALYSÉ PAR CYP2D6

Country Status (38)

Country Link
US (3) US20030144220A1 (fr)
EP (1) EP1242058A1 (fr)
JP (1) JP3704290B2 (fr)
KR (1) KR20010104388A (fr)
CN (1) CN1479628A (fr)
AP (1) AP2001002290A0 (fr)
AR (1) AR019507A1 (fr)
AU (1) AU774923B2 (fr)
BG (1) BG106075A (fr)
BR (1) BR0009564A (fr)
CA (1) CA2367052A1 (fr)
CZ (1) CZ20013599A3 (fr)
DZ (1) DZ3032A1 (fr)
EA (1) EA005158B1 (fr)
EE (1) EE200100524A (fr)
GE (1) GEP20043251B (fr)
GT (1) GT200000041A (fr)
HR (1) HRP20010722A2 (fr)
HU (1) HUP0300535A2 (fr)
ID (1) ID30355A (fr)
IL (1) IL145451A0 (fr)
IS (1) IS6083A (fr)
MA (1) MA26728A1 (fr)
MY (1) MY132882A (fr)
NO (1) NO20014858L (fr)
NZ (1) NZ514466A (fr)
OA (1) OA11858A (fr)
PA (1) PA8493401A1 (fr)
PE (1) PE20010051A1 (fr)
PL (1) PL359022A1 (fr)
SK (1) SK13832001A3 (fr)
SV (1) SV2002000049A (fr)
TN (1) TNSN00071A1 (fr)
TR (1) TR200102876T2 (fr)
UY (1) UY26092A1 (fr)
WO (1) WO2000059486A2 (fr)
YU (1) YU70101A (fr)
ZA (1) ZA200108158B (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
CA2451914A1 (fr) * 2001-08-08 2003-02-20 John-Michael Sauer Polytherapie servant au traitement de troubles neurologiques
WO2003016274A2 (fr) * 2001-08-21 2003-02-27 Sepracor, Inc. Piperidines 2-substitue, ligands pour des recepteurs et des transporteurs de monoamines
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
DE10319741A1 (de) * 2003-04-30 2004-11-18 Basf Ag Verfahren zur Verbesserung der Bedruckbarkeit von Papier und Papierprodukten beim Bedrucken mit Hilfe des Tintenstrahldruckverfahrens
EP1944042A1 (fr) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinaisons pour le traitement HCV
JP2007519706A (ja) * 2004-01-30 2007-07-19 ファイザー・インク Ｈｉｖプロテアーゼ阻害剤及びシトクロームｐ４５０酵素活性阻害剤を含んでなる組成物
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (fr) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methodes d'administration d'iloperidone
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (fr) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
EP1817023A4 (fr) * 2004-11-16 2010-08-18 Limerick Biopharma Inc Procedes et compositions de traitement de douleurs
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP2518079A3 (fr) 2006-04-11 2012-12-12 Novartis AG Inhibiteurs du VHC/VIH et leur utilisation
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
JP5745855B2 (ja) * 2007-11-28 2015-07-08 セコイア、ファーマシューティカルズ、インコーポレイテッドＳｅｑｕｏｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． シトクロムｐ４５０ ２ｄ６を阻害するための組成物および方法
WO2010062690A1 (fr) * 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combinaison de composés de morphinane et d’antidépresseur pour le traitement de l’affect pseudobulbaire, des maladies neurologiques, de la douleur incurable et chronique et des lésions cérébrales
EP2396028A2 (fr) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Polythérapie contre le hcv comprenant de l'interféron pégylé, de la ribavirine et de la telaprevir
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
CN101824467B (zh) * 2009-12-29 2012-07-18 广州益善生物技术有限公司 Cyp2d6基因突变检测液相芯片及检测方法
WO2012109646A1 (fr) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Traitement du vhc chez des patients infectés par le vih
US10716784B2 (en) * 2013-03-07 2020-07-21 Mindlab LLC Pain medicine combination and uses thereof
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200261431A1 (en) 2019-01-07 2020-08-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US9408815B2 (en) 2013-11-05 2016-08-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
EP3981403A1 (fr) 2013-11-05 2022-04-13 Antecip Bioventures II LLC Compositions et procédés comprenant du bupropion ou des composés apparentés et du dextrométhorphane
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
EP2985036A3 (fr) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Antagonistes de CYP2J2 dans le traitement de la douleur
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020095979A1 (fr) * 2018-11-08 2020-05-14 大日本住友製薬株式会社 Agent thérapeutique pour une maladie du système nerveux central comprenant de la tipépidine
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
AU2021292943B2 (en) * 2020-06-15 2024-04-04 Universitätsspital Basel MDMA response prediction
CN112697921B (zh) * 2020-12-24 2022-08-30 北京和合医学诊断技术股份有限公司 马普替林的检测方法
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
WO2023039187A1 (fr) * 2021-09-10 2023-03-16 ATAI Life Sciences AG Polythérapie par ibogaïne
WO2023233051A1 (fr) * 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Compositions injectables à libération prolongée destinées à être utilisées dans le cadre du traitement par rispéridone en association avec des inhibiteurs de l'enzyme cyp2d6
US12036191B1 (en) * 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2024064825A1 (fr) * 2022-09-21 2024-03-28 Axsome Therapeutics, Inc. Composés et combinaisons de ceux-ci pour le traitement d'états neurologiques et psychiatriques
JP2025531623A (ja) * 2022-09-28 2025-09-22 オリオン コーポレーション タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166207A (en) * 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
BG106075A (en) 2002-06-28
AU3185000A (en) 2000-10-23
OA11858A (en) 2006-03-02
US20030144220A1 (en) 2003-07-31
CN1479628A (zh) 2004-03-03
GT200000041A (es) 2001-09-27
DZ3032A1 (fr) 2004-03-27
IL145451A0 (en) 2002-06-30
EA200100934A1 (ru) 2002-08-29
SV2002000049A (es) 2002-12-02
ID30355A (id) 2001-11-22
NO20014858L (no) 2001-12-05
PE20010051A1 (es) 2001-02-06
TNSN00071A1 (fr) 2005-11-10
EE200100524A (et) 2002-12-16
KR20010104388A (ko) 2001-11-24
US20040018253A1 (en) 2004-01-29
WO2000059486A2 (fr) 2000-10-12
PA8493401A1 (es) 2002-07-30
US20040028755A1 (en) 2004-02-12
UY26092A1 (es) 2000-10-31
CA2367052A1 (fr) 2000-10-12
IS6083A (is) 2001-09-25
YU70101A (sh) 2004-05-12
JP2003523936A (ja) 2003-08-12
TR200102876T2 (tr) 2006-12-21
WO2000059486A8 (fr) 2002-07-25
ZA200108158B (en) 2003-07-24
CZ20013599A3 (cs) 2003-01-15
JP3704290B2 (ja) 2005-10-12
EA005158B1 (ru) 2004-12-30
AU774923B2 (en) 2004-07-15
HRP20010722A2 (en) 2002-08-31
AP2001002290A0 (en) 2001-12-31
GEP20043251B (en) 2004-06-25
HUP0300535A2 (hu) 2003-07-28
AR019507A1 (es) 2002-02-20
BR0009564A (pt) 2002-01-08
NZ514466A (en) 2004-10-29
MY132882A (en) 2007-10-31
NO20014858D0 (no) 2001-10-05
SK13832001A3 (sk) 2004-01-08
EP1242058A1 (fr) 2002-09-25
PL359022A1 (en) 2004-08-23

Similar Documents

Publication Publication Date Title
TNSN00071A1 (fr) Composition pharmaceutique comprenant un inhibiteur de cyp2d6 et un medicament a metabolisme catalyse par cyp2d6
TNSN00252A1 (fr) Compositions pharmaceutiques engendrant des concentrations accrues de medicaments
HUP0003351A2 (hu) 2-Szubsztituált-4,5-diaril-imidazolok, eljárás e vegyületek előállítására, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003053330A3 (fr) Nouveaux composés
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
SE0001899D0 (sv) New compounds
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
WO1999038877A3 (fr) Derives de 2-(purine-9-yl)-tetrahydrofurane-3,4-diol
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
CA2304704A1 (fr) Formulations et procedes de reduction de la toxicite d'agents antineoplasiques
SI1465626T1 (sl) Farmacevtski sestavki (komplet), ki obsegajo dihidropiridionske spojine in imunoregulacijsko (ali protivnetno) sredstvo, in njihove uporabe
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
PL321791A1 (en) Method of and compositions and sets of agents for enhancing oral biological availability of pharmaceutic agents
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
GEP20032958B (en) Adenosine Derivatives
GEP20063799B (en) Tropane derivatives useful in therapy
BRPI0618380A2 (pt) combinação farmacêutica e seu uso
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo